Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore
M Premikha, Calvin J. Chiew, Wycliffe Enli Wei, Yee‐Sin Leo, Benjamin Ong, David Chien Lye, Vernon J. Lee, Kelvin Bryan Tan
Abstract
Compared with individuals vaccinated with Pfizer-BioNTech/Comirnaty, recipients of Sinovac-CoronaVac and Sinopharm were 2.37 (95% CI, 2.29-2.46) and 1.62 (95% CI, 1.43-1.85) times more likely to be infected with coronavirus disease 19, respectively, while individuals vaccinated with Moderna were 0.42 (95% CI, 0.25-0.70) times less likely to develop severe disease.
Topics & Concepts
MedicineDiseaseVirologyCoronavirusCoronavirus disease 2019 (COVID-19)VirusViral diseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Immunology2019-20 coronavirus outbreakInternal medicineOutbreakInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyAnimal Virus Infections Studies